Navigation Links
Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
Date:9/17/2008

EXTON, Pa., Sept. 17 /PRNewswire/ -- BioTrends Research Group, Inc. released its third annual TreatmentTrends(TM): The Use of Biologic Agents in Rheumatology publication, providing insight into the management of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS). This report is based on responses to an online survey completed by 100 US Rheumatologists in August 2008.

According to the study, the majority of Rheumatologists reported an increase in their use of biologics for the treatment of RA, PsA, and AS in the past six months. In most cases, biologic agents are being prescribed for RA, however, AS and PsA together account for approximately 20% of the cases for which the Rheumatologists are prescribing biologics. More than half of the respondents expect their use of biologics in RA and PsA to increase in the next six months, and 39% expect their use of these agents for "other" conditions to increase as well.

While the increased use of biologics was seen across the board, certain physician types, particularly those newer to practice, seem to be more aggressive in their use of these agents. Bristol Myers Squibb's Orencia (abatacept) experienced significant share gains in the past year and a higher percent of Rheumatologists report using Orencia this year compared to last. Despite these gains, the TNF-alpha antagonists (Amgen/Wyeth's Enbrel, Abbott's Humira, and Cenotcor's Remicade) still collectively account for more than 80% of the biologic share in RA. While all of the biologics are negatively impacted by out of pocket costs to patients, a top obstacle to expanded Orencia use is its second/third line status ("patients do well on the first line choice") and the top obstacles to expanded Rituxan use are centered around safety and tolerability concerns. Safety concerns with Rituxan may continue with the recent news of the first fatal case of PML in a patient taking Rituxan for RA. Most respondents indicated that Orencia is typically chosen after one TNF-alpha failure while Genentech's Rituxan is reserved until patients have failed two or more biologic agents.

Among the Rheumatologists anticipating an increase in the use of biologics in RA, 59% cite that newer agents are the main reason for the expectation of expanded use. A number of new biologics with unique mechanisms of action may soon be available for use in RA. Improved and sustained efficacy in new products and oral formulations are highly desirable. UCB's Cimzia is already on the market with an indication for Crohn's Disease, and while Rheumatologists are interested in this compound, off label use is limited. Among biologics in development, familiarity and interest are highest for Roche's Actemra, an anti-IL-6 receptor monoclonal antibody which could be available by the end of the year.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact BioTrends at (610) 363-3872 or http://www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
2. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
3. China Biologic Products to Present at the SIG Beijing Management Summit
4. China Biologics Production Facility Renews GMP Certification
5. ETEX Launches Innovative Osteoinductive Orthobiologic, EquivaBone(TM)
6. China Biologic Products Reports Second Quarter 2008 Results
7. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
8. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
9. China Biologic Products Announces Second Quarter 2008 Results Conference Call
10. Tips on how to build a better home for biological parts
11. FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
Breaking Biology News(10 mins):